Although the mRNA-SP+P1 vaccine did not completely prevent ATCC M129 infection, it significantly mitigated infection severity, lung M. pneumoniae loads, and pulmonary inflammation, demonstrating a protective effect. This evidence concerns the gene TFF2 and infection.